Professor of Medicine, Dana-Farber Cancer Institute
Internal Medicine
Dr. William G. Kaelin Jr., MD
|
|
Give Review
William Kaelin practices Internal Medicine. He went to medical school at Duke University School of Medicine. Duke University School of Medicine is a top medical university. Duke University School of Medicine is ranked 8 in research and 29 in primary care medicine He has 2 awards "Elected Member" and "Investigator". William G. Kaelin Jr. is a published MD. He has 100 papers published. The most current publication "EGLN1 Inhibition and Rerouting of -Ketoglutarate Suffice for Remote Ischemic Protection."
Publications
- EglN2 associates with the NRF1-PGC1α complex and controls mitochondrial function in breast cancer.
- Genetic Evidence of a Precisely Tuned Dysregulation in the Hypoxia Signaling Pathway during Oncogenesis.
- A genetic mechanism for Tibetan high-altitude adaptation.
- Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase.
- A phase I study of cabozantinib (XL184) in patients with renal cell cancer.
- D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
- SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer.
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins.
- Twenty-fifth annual Pezcoller Symposium: Metabolism and tumorigenesis.
- What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.
- Influence of metabolism on epigenetics and disease.
- (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible.
- Molecular biology. Use and abuse of RNAi to study mammalian gene function.
- The VHL/HIF axis in clear cell renal carcinoma.
- Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion.
- Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
- Genetic and Functional Studies Implicate HIF1? as a 14q Kidney Cancer Suppressor Gene.
- New insights into the biology of renal cell carcinoma.
- Good COP1 or bad COP1? In vivo veritas.
- FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis.
- New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein.
- Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy.
- Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase.
- Reactivation of hepatic EPO synthesis in mice after PHD loss.
- Prostate cancer: beta control your hormones.
- Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase.
- A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo.
- SDH5 mutations and familial paraganglioma: somewhere Warburg is smiling.
- HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice.
- Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.
- Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein.
- Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.
- Kidney cancer: now available in a new flavor.
- A role for mammalian Sin3 in permanent gene silencing.
- Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen.
- Senescence triggered by the loss of the VHL tumor suppressor.
- Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
- The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor.
- Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure.
- Nineteenth Annual Pezcoller Symposium: hypothesis-driven clinical investigation in cancer.
- pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2.
- Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations.
- The retinoblastoma binding protein RBP2 is an H3K4 demethylase.
- The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo.
- Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.
- The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.
- The von hippel-lindau tumor suppressor protein: an update.
- Molecular pathways in renal cell carcinoma--rationale for targeted treatment.
- Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.
- Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production.
- Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma.
- The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing.
- Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer.
- The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase.
- Binding of pRB to the PHD protein RBP2 promotes cellular differentiation.
- ROS: really involved in oxygen sensing.
- Proline hydroxylation and gene expression.
- Bioluminescent imaging of ubiquitin ligase activity: measuring Cdk2 activity in vivo through changes in p27 turnover.
- Role of VHL gene mutation in human cancer.
- Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.
- Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist.
- Innovations and challenges in renal cancer: consensus statement from the first international conference.
- The von Hippel-Lindau tumor suppressor gene and kidney cancer.
- Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes.
- Bioluminescent imaging of Cdk2 inhibition in vivo.
- pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development.
- Gleevec: prototype or outlier?
- Analysis of von Hippel-Lindau hereditary cancer syndrome: implications of oxygen sensing.
- Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth.
- The von Hippel-Lindau gene, kidney cancer, and oxygen sensing.
- Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination.
- TSC2 regulates VEGF through mTOR-dependent and -independent pathways.
- The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer.
- E2F1 as a target: promoter-driven suicide and small molecule modulators.
- Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways.
- Chemosensitivity linked to p73 function.
- HIF hydroxylation and the mammalian oxygen-sensing pathway.
- VHL and kidney cancer.
- Detection of peptides, proteins, and drugs that selectively interact with protein targets.
- Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor.
- Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhi...
- How oxygen makes its presence felt.
- Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling.
- The human p73 promoter: characterization and identification of functional E2F binding sites.
- Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.
- Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependen...
- Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.
- Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report.
- Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex.
- Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing.
- p53 family update: p73 and p63 develop their own identities.
- Differential control of transcription by DNA-bound cyclins.
- Human cytotrophoblast expression of the von Hippel-Lindau protein is downregulated during uterine invasion in situ and upregulated by hypoxia in vitro.
- von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
- Role of the newer p53 family proteins in malignancy.
- HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.
- The von Hippel-Lindau tumor suppressor gene.
- The von Hippel-Lindau tumor suppressor protein.
- EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection.
Schools
Duke University
Dana Farber Cancer Institute
Duke University Med Center
Johns Hopkins Hospital
Doctors Specialties
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Awards
- Elected Member
- Investigator
Education
-
Johns Hopkins University -
Duke University Hospital -
Duke University School of Medicine
Hospital
-
Dana-Farber Cancer Institute
Helpful Reviews
Similar Doctors
|
|
Dr. Andrew S. Paulson, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anica Law, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca A. Miksad, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julia H. Hayes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer S. Temel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Kim, MD |
|
|
Dr. Bijay Acharya, MD
This Doctor is OpenDoctor Recommended.
|